The re-born Esperion Therapeutics is once again teaming up with researchers at the Cleveland Clinic to find new cholesterol therapies. The deal revives a relationship that was terminated when Pfizer, which had acquired the old Esperion, pulled out of Ann Arbor in 2007. "When we re-established Esperion in 2008, our goal was to continue this research tradition," said CEO Roger Newton. "We are once again bringing together the outstanding resources and expertise at both Esperion and Cleveland Clinic to advance important research efforts in HDL in the years ahead." Report